AstraZeneca to shutter Indian R&D site
This article was originally published in Scrip
AstraZeneca is shuttering its Indian R&D site, Avishkar, in Bangalore as part of efforts to "simplify" its research footprint and focus on just its core areas – the oncology, cardio-metabolism and the respiratory, inflammation and autoimmune segments.
You may also be interested in...
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.